VR FOR MEDTECH
Lightpoint Medical
How immersive visualization contributed to a €33M acquisition
Services // IMMERSIVE // VIRTUAL REALITY
The challenge
Lightpoint Medical was developing SENSEI®, a revolutionary AI-powered technology for precision cancer surgery using DaVinci robotic systems. They faced two critical challenges:
Product Challenge
Surgeons needed real-time AI imaging data integrated seamlessly into their surgical workflow without disrupting focus during life-saving cancer operations.
Investment Challenge
They needed compelling materials to communicate their technology’s value to investors and potential acquirers, not just to describe the innovation, but make it tangible and experienceable.
Our approach
We created a multi-phase immersive visualization solution designed for both clinical validation and investor communication:
Phase 1: Surgical Documentation
Filmed live surgery at Hospital del Mar, Barcelona (December 2021)
Captured stereoscopic 3D HD footage from the Da Vinci robot console
Created materials for clinical presentations to other surgeons
Phase 2: VR Interface Demo
Built an immersive VR demonstration using real surgical footage augmented with AI/ML data visualizations
Designed multiple interface layout options for usability testing
Validated designs with practicing surgeons to ensure interfaces would support – not disrupt – surgical precision
Our focus: maximizing interface clarity and surgeon usability through evidence-based design.
The outcome
The VR visualizations and surgical documentation became key assets in Lightpoint Medical’s investor presentations and clinical demonstrations.
In November 2023, Telix Pharmaceuticals, a publicly-traded precision medicine company, acquired Lightpoint Medical and its SENSEI® technology for €33 million.
Our work helped Lightpoint Medical:
- Validate surgical interface designs with real surgeons before production
- Communicate complex surgical AI technology to investors through immersive experience
- Demonstrate both clinical value and commercial potential
Today, SENSEI® technology is deployed in urologic cancer surgery as part of Telix Pharmaceuticals’ precision medicine platform.
Team
Giles Pooley
Executive Producer
Milo De Prieto
Producer/Director
Mike van der Noord
Creative Director and Developer
Key results
VR demo validated
with practicing surgeons
Materials used
in investor presentations
Evidence-based specifications
for production interface
Material contributed to €33M
acquisition by Telix Pharmaceuticals
Technology now deployed
in clinical cancer surgery
